Both Eli Lilly and Company (NYSE:LLY) and GW Pharmaceuticals plc (NASDAQ:GWPH) compete on a level playing field in the Drug Manufacturers – Major industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	24.56B	4.87	3.23B	3.30	38.61
GW Pharmaceuticals plc	26.62M	192.79	287.62M	-10.50	0.00

Demonstrates Eli Lilly and Company and GW Pharmaceuticals plc earnings per share, gross revenue and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	13.15%	26.4%	7.4%
GW Pharmaceuticals plc	-1,080.47%	-71.4%	-62.4%

Volatility and Risk

A 0.32 beta indicates that Eli Lilly and Company is 68.00% less volatile compared to Standard & Poor’s 500. GW Pharmaceuticals plc’s 2.83 beta is the reason why it is 183.00% more volatile than Standard & Poor’s 500.

Liquidity

The current Quick Ratio of Eli Lilly and Company is 1.4 while its Current Ratio is 1.7. Meanwhile, GW Pharmaceuticals plc has a Current Ratio of 6.7 while its Quick Ratio is 6.3. GW Pharmaceuticals plc is better positioned to pay off its short-term and long-term debts than Eli Lilly and Company.

Dividends

Eli Lilly and Company pays out an annual dividend of $2.25 per share while its dividend yield is 1.8%. GW Pharmaceuticals plc does not pay a dividend.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Eli Lilly and Company and GW Pharmaceuticals plc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Eli Lilly and Company	0	4	4	2.50
GW Pharmaceuticals plc	0	1	7	2.88

Eli Lilly and Company has a 6.66% upside potential and a consensus price target of $131.25. Competitively the consensus price target of GW Pharmaceuticals plc is $173.5, which is potential 3.38% upside. Based on the analysts view we can conclude, Eli Lilly and Company is looking more favorable than GW Pharmaceuticals plc.

Institutional & Insider Ownership

Institutional investors owned 81.9% of Eli Lilly and Company shares and 89.7% of GW Pharmaceuticals plc shares. Insiders owned 11.5% of Eli Lilly and Company shares. Competitively, GW Pharmaceuticals plc has 0.62% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Eli Lilly and Company	2.88%	6.34%	10.33%	21.01%	66.61%	10.15%
GW Pharmaceuticals plc	16.99%	23.59%	45.17%	19.37%	60.19%	81.16%

For the past year Eli Lilly and Company’s stock price has smaller growth than GW Pharmaceuticals plc.

Summary

Eli Lilly and Company beats GW Pharmaceuticals plc on 10 of the 14 factors.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the companyÂ’s product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.